Two experimental DNA vaccines to prevent Ebola are safe, according to new research and may help contain the deadly disease.
The first trial of filovirus vaccines in Africa, published in The Lancet, shows a similar immune response in healthy Ugandan adults as reported in healthy Americans earlier this year.
Doctor Julie Ledgerwood, of the US National Institutes of Allergy and Infectious Diseases (NIAID), said: “This is the first study to show comparable safety and protection of an experimental Ebola vaccine in an African population.
"This is particularly encouraging because those at greatest risk of Ebola live primarily in Africa, and diminished vaccine protection in African populations has been seen for other diseases."
Scientists from the NIAID developed the DNA vaccines that code for Ebola virus proteins from the Zaire and Sudan strains and the Marburg virus protein.